Contraceptive Innovations: Needs and Opportunities

  • Sheldon J. Segal
Part of the Reproductive Biology book series (RBIO)


People who wish to limit their fertility do so primarily in pursuit of family or individual aspirations to enhance their chances for personal fulfillment and to provide a good home and opportunities for their children. These aspirations are often frustrated, as high rates of unwanted pregnancy exist side by side with the desire to limit fertility. Contributing to this paradox is the fact that contraceptive measures, under conditions of actual use, often do not provide the desired protection against pregnancy (Trussell and Kost, 1987).


Oral Contraceptive Acquire Immune Deficiency Syndrome Contraceptive Method Tetanus Toxoid Vaginal Ring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Affandi, B., S.S.I. Santoso, Djajadilaga, W. Hadisaputra, F.A. Moeloek, J. Prihartono, F. Lubis, and R.S. Samil 1987 Five-year experience with Norplant®. Contraception 34(4):417–428.CrossRefGoogle Scholar
  2. Ahren, T., A. Victor, H. Lithell, B. Vessby, T.M. Jackanicz, and E.D.B. Johansson 1983 Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins. Contraception 28(4):315–327.PubMedCrossRefGoogle Scholar
  3. Alvarez, F., A. Faundes, E. Johansson, and E. Coutinho 1983 Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills. Fertility and Sterility 41:120–123.Google Scholar
  4. Archer, D.F. 1988 Phase I biodegradable norethindrone. In Six Month Technical Report Summary, October 1, 1987-March 31, 1988. Norfolk: Contraceptive Research and Development, Eastern Virginia Medical School.Google Scholar
  5. Atkinson, L.E., R. Lincoln, and J.D. Forrest 1986 The next contraceptive revolution. Family Planning Perspectives 16 (l) :19–26.Google Scholar
  6. Bygdeman, M., and M.L. Swahn 1985 Progesterone receptor blockage: Effect on uterine contractility and early pregnancy. Contraception 32:45–61.PubMedCrossRefGoogle Scholar
  7. Collins, R.L., and G.D. Hodgen 1986 Blockage of the spontaneous midcycle gonadotrophin surge in monkeys, by RU 486: A progesterone antagonist or agonist? Journal of Clinical Endocrinology and Metabolism 63:127.CrossRefGoogle Scholar
  8. Coutinho, E.M., and J.C. De Souza 1968 Conception control by monthly injections of medroxyprogesterone suspension and a long-acting oestrogen. Journal of Reproduction and Fertility 15:209–214.PubMedCrossRefGoogle Scholar
  9. Coutinho, E.M., G.A. Boulanger, and M.T. Goncalves 1986 Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone. American Journal of Obstetrics and Gynecology 155(4):761–767.PubMedGoogle Scholar
  10. Coutinho, E.M., J.C. De Souza, and A.L Csapo 1966 Reversible sterility induced by medroxyprogesterone injections. Fertility and Sterility 17(2):261–266.PubMedGoogle Scholar
  11. Coutinho, E.M., E.J. Coutinho, M.T.R. Concaves, and I.C. Barbosa 1982 Ovulation suppression in women following vaginal administration of oral contraceptive tablets. Fertility and Sterility 38:380–381.PubMedGoogle Scholar
  12. Coutinho, E.M., A.R. de Silva, C. Carreira, I. Barbosa, V. Dourado-Silva, and I. Sivin 1984a Contraception with single implants and mini-implants of ST-1435. Pp. 450–455 in G.I. Zatuchni, A. Goldsmith, J.D. Shelton, and J.J. Sciarra, eds.. Long-Acting Contraceptive Delivery Systems, Philadelphia, Pa.: Harper k. Row.Google Scholar
  13. Coutinho, E.M., A.R. de Silva, C. Carreira, V. Rodrigues, and M.T. Goncalves 1984b Conception control by vaginal administration of pills containing ethinylestradiol and dl-norgestrel. Fertility and Sterility 42:478–481.PubMedGoogle Scholar
  14. Coutinho, E.M., J.F.Melo, I. Barbosa, and S.J. Segal 1984c Antispermatogenic action of gossypol in men. Fertility and Sterility 42:424–429.Google Scholar
  15. Diaz, S., M. Pavez, H. Cardenas, and H.B. Croxatto 1987 Recovery of fertility and outcome pregnancies after the removal of Norplant® subdermal implants or copper-T lUDs. Contraception 35(6):569–579.PubMedCrossRefGoogle Scholar
  16. Griffin, P.D. 1986 A fertility regulation vaccine based on the carboxyl-terminal peptide of the beta subunit of human chorionic gonadotrophin. Pp. 43–59 in G.P. Talwar, ed.. Immunological Approaches to Contraception and Promotion of Fertility. New York: Plenum Press.Google Scholar
  17. Griffin, P.D. 1988 Vaccines for fertility regulation. Pp. 177–197 in Research in Human Reproduction: WHO Special Programme of Research, Development and Research Training in Human Reproduction. Biennial Report, 1986–1987. Geneva: World Health Organization. Google Scholar
  18. Gu, S., M. Du, Y.D. Yuan, L.D. Zhang, M.F. Xu, Y-L Liu, S.H. Wang, S.L. Wu, P-Z Wang, Y-L Gao, X. He, L-F Qi, C-R Chen, Y.P. Liu, P. Mo, and I. Sivin 1988 A two-year study of acceptability, side effects and effectiveness of Norplant® and Norplant®-2 implants in the People’s Republic of China.Contraception 38(6):641–658.PubMedCrossRefGoogle Scholar
  19. Gupta, G.N. 1977 Sustained absorption of 3H-norgestrel from s.c. fused pellets in rats: A potential totally bioabsorbable implant for human contraception (Ab #3833). Federal Proceedings 36:977.Google Scholar
  20. Gupta, G.N., B.B. Saxena, R. Landesman, and W.J. Ledger 1984 Subcutaneous bioabsorbable pellets of norethindrone for contraception in women: Phase I: Clinical study, Fertility and Sterility 41 (5):726- 731.PubMedGoogle Scholar
  21. Hall, P.E., and C. d’Arcangues 1988 Long-acting methods of fertility regulation. Pp. 129–150 in Research in Human Reproduction, WHO Special Programme of Research, Development and Research Training in Human Reproduction. Biennial Report, 1986–1987. Geneva: World Health Organization.Google Scholar
  22. Heller, C.G., W.M. Laidlaw, H.T. Harvey, and W.O. Nelson 1958 Effects of progestational compounds on the reproductive process of the human male. Annals of the New York Academy of Sciences 71:649–661.PubMedCrossRefGoogle Scholar
  23. Hermann, W., R. Wyss, A. Ryondel, D. Philibert, G. Teutsch, E. Sakiz, and E.E. Baulieu 1982 Effet d’un stercide anti-progesterone chez la femme. Comptes Rendus de VAcademie des Sciences Paris 294:933–938.Google Scholar
  24. Jennings, M.B., and M.M. Reidenberg 1988 Adaptation to nephrotoxic chemicals. Proceedings of the Society for Experimental Biology and Medicine 189:338–343.Google Scholar
  25. Landgren, B.M. 1987 Vaginal delivery system. Pp. 165–180 in E. Diszfalusy and M. Bygde- man, eds., Fertility Regulation Today and Tomorrow. New York: Raven Press.Google Scholar
  26. Lee, N.C., G.L. Rubin, and R. Boruck 1988The intrauterine device and pelvic inflammatory disease revisited: New results from the Women’s Health Study. Obstetrics and Gynecology 72 (l) : l-6Google Scholar
  27. Lei, H.P., and Z.Y. Hu 1981 The mechanisms of action of vacation pills. Pp. 70–82 in C.C. Fen, D. Griffin, and A. Woolman, eds., Recent Advances in Fertility Regulation. Geneva: Atar S.A.Google Scholar
  28. Liu, G.Z., and K.C. Lyle 1987 Clinical trial of gossypol as a male contraceptive drug. IL Hypokalemia study. Fertility and Sterility 8:462–465.Google Scholar
  29. Liu, G.Z., K.C. Lyle, and C. Jian 1987 Clinical trial of gossypol as a male contraceptive drug. L Efficacy study. Fertility and Sterility 48:459–461.PubMedGoogle Scholar
  30. Luukkainen, T., J. Toivonen, and P. Lahteenmaki 1987 Medicated intrauterine devices. Pp. 153–163 in E. Diczfalusy and M. Bygdeman, eds.. Fertility Regulation Today and Tomorrow. New York: Raven Press.Google Scholar
  31. Matlin, S.A., A. Belengeur, G.R. Tyson, and A.N. Brookes 1987 Resolution of gossypol: Analytical and large scale preparative HPLC on non-chiral phases. Journal of High Resolution Chromatography Communications 10:86–91.CrossRefGoogle Scholar
  32. Matlin, S.A., R. Zhou, G. Bialy, R.P. Blye, R.H. Naqui, and M.C. Lindberg (—)-Gossypol: An active male antifertility agent. Contraception 31:141–149.30Google Scholar
  33. Mauldin, W.P., and S.J. Segal 1985 Prevalence of Contraceptive Use in Developing Countries: A Chart Book. New York: Rockefeller Foundation. 1988 Prevalence of contraceptive use: Trends and issues. Studies in Family Planning 19:335–353.CrossRefGoogle Scholar
  34. Meng, G.D., J.C. Zhu, Z.W. Chen, and L.T. Wong 1988 Recovery of sperm production following the cessation of gossypol treatment: A two center study in China. International Journal of Andrology 11:1–11.PubMedCrossRefGoogle Scholar
  35. Mishell, D.R., D.E. Moore, S. Roy, F.F. Brenner, and M.A. Page 1978 Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.American Journal of Obstetrics and Gynecology 130:55–62.PubMedGoogle Scholar
  36. Mishell, D.R., M. Talas, A.F. Parlow, and D.L. Moyer Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate.American Journal of Obstetrics and Gynecology 107:100.Google Scholar
  37. Monahan, J., J. Rivier, R. Burgus, S. Amos, W. Blackwell, W. Vale, and R. Guillemin Synthese totale par phase solide d’un decapeptide qui stimule la secretion des gonadotropines hypophysaires LH et FSH. Comptes Rendus de VAcademie des Sciences Paris 273:508–510.Google Scholar
  38. Mora, G., A. Faundes, and U. Pastore 1974 Clinical evaluation of an oral progestin contraceptive, R-2323, 5 mg. administered at weekly intervals. Contraception 10:145–148.PubMedCrossRefGoogle Scholar
  39. Nash, H., G.P. Talwar, S.J. Segal, T. Luukkainen, E.D.B. Johansson, J. Vasquez, E. Coutinho, and K. Sundaram 1980 Observations on the antigenicity and clinical effects of a candidate antipregnancy vaccine: Beta-subunit of human chorionic gonadotropin linked to the tetanus toxoid.Fertility and Sterility 34 (4): 328- 335.PubMedGoogle Scholar
  40. National Coordinating Group on Male Antifertility Agents 1978 Gossypol: A new antifertility agent for males. Chinese Medical Journal 4 (6):417–428.Google Scholar
  41. Ngugi, E.N., F.A. Plummer, D.W. Cameron, M. Bosire, and J. Ndinya-Achda Effect of an AIDS Education Program on Increasing Condom Use in a Cohort of Nairobi Prostitutes. P. 157. Paper presented at the III International Conference on Acquired Immunodeficiency Syndrome (AIDS), June 1–5, Washington, D.C.Google Scholar
  42. Nieman, L.K., T.M. Choate, G.P. Chrousos, and D.L. Healy The progesterone antagonist RU 486: A potential new contraceptive agent. New England Journal of Medicine 316:187–191.Google Scholar
  43. Nieschlag, E. 1985 Reasons for abandoning immunization against FSH as an approach to male fertility regulation. Pp. 395–400 in G.I. Zatuchni, A. Goldsmith, J.M. Spieler, and J.J. Sciarra, eds., Male Contraception. Philadelphia, Pa.: Harper &: Row.Google Scholar
  44. Odlind, V. Report to the International Committee on Contraception Research. New York: Population Council.Google Scholar
  45. Population Council 1988 Contraceptive subdermal implants. NORPLANT ® Worldwide 10:1- 4.Google Scholar
  46. Psychoyos, A., and J.M. Husson 1987 Antiprogestagens: Basic Research and Clinical Aspects. Paper presented at the Second International Symposium of the Japan Family Planning Association, Tokyo, October 24.Google Scholar
  47. Salah, M., A.G.M. Ahmed, M. Abo-Eloyoun, and M.M. Shaaban 1987 Five-year experience with Norplant® implants in Assiut, Egypt. Contraception 35 (6):543–550.PubMedCrossRefGoogle Scholar
  48. Schally, A.V., A. Arimura, Y. Baba, R.M. Nair, H. Matsuo, T.W. Redding, and L. Debeljuk 1971 Isolation and properties of the FSH and LH-releasing hormone. Biochemistry and Biophysics Research Communications 16:392–399.Google Scholar
  49. Schearer, S.B., F. Alvarez-Sanchez, J. Anselmo, P. Brenner, E. Coutinho, A. Latham-Faundes, J. Frick, B. Heinild, and E.D. Johansson 1978 Hormonal contraception for men. International Journal of Andrology 2(Suppl.):680–712.CrossRefGoogle Scholar
  50. Segal, S.J. Contraceptive technology: Current and prospective methods. Milbank Memorial Fund Quarterly, October 49 (4) [Part 2]:145–171.Google Scholar
  51. Contraceptive research: A male chauvinist plot?Family Planning Perspectives 4(3):21–25. 1984 Seeking better contraceptives. Populi 11(2):29.Google Scholar
  52. Segal, S.J., and H.B. Croxatto 1967 Single Administration of Hormones for Long-Term Control of Reproductive Function. Paper presented at the twenty-third meeting of the American Fertility Society, April 14–16, Washington, D.C.Google Scholar
  53. Segal, S.J., and W.P. Mauldin Contraceptive choices: Who, what, why? Pp. 305–317 in E. Diczfalusy and M. Bygdeman, eds..Fertility Regulation Today and Tomorrow. Serono Symposium, vol. 36. New York: Raven Press.Google Scholar
  54. Sivin, I. International experience with Norplant®-2 contraceptives. Studies in Family Planning 19(2):81–94.Google Scholar
  55. Sivin, I., and H.J. Tatum 1981 Four years of experience with the TCu-380A intrauterine contraceptive device. Fertility and Sterility 36:159–163.PubMedGoogle Scholar
  56. Sivin, L, D.R. Mishell, A. Victor, V. Brache, T. Jackanicz, and H.A. Nash 1981a A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. I. Use effectiveness: An international comparative trial. Contraception 24:341–358.PubMedCrossRefGoogle Scholar
  57. Sivin, L, D.R. Mishell, A. Victor, V. Brache, T. Jackanicz, and H.A. Nash 1981b A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. II. Subjective and objective measures of effects. Contraception 24:359–376.PubMedCrossRefGoogle Scholar
  58. Sundaram, K., A. Didolkar, R. Thau, M. Chaudhuri, and F. Schmidt 1988 Antagonists of luteinizing hormone releasing hormone bind to rat mast cells and induce histamine release. Agents and Actions 25:307–313.PubMedCrossRefGoogle Scholar
  59. Swahn, M.L., and M. Bygdeman 1988 The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. British Journal of Obstetrics and Gynecology 95(2):126–134.CrossRefGoogle Scholar
  60. Talwar, G.R, and O. Singh 1988 Birth control vaccines inducing antibodies against chorionic gonadotropin. Pp. 183–197 in G.P. Talwar, ed., Contraception Research for Today and the Ninety’s. New York: Springer-Verlag.CrossRefGoogle Scholar
  61. Talwar, G.P., N.C. Sharma, S.K. Dubey, M. Salahuddin, C. Das, S. Rama- krishnan, S. Kumar, and V. Hingorani 1976 Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid. Proceedings of the National Academy of Sciences USA 73(l):218–222.CrossRefGoogle Scholar
  62. Teutsch, G. Analogues of RU 486 for the mapping of the progestin receptor: Synthetic and structural aspects. Pp. 27–47 in E.E. Baulieu and S.J. Segal, eds., The Antiprogestin Steroid Ru 486 and Human Fertility Control. New York: Plenum Press.Google Scholar
  63. Thau, R.B., C.B. Wilson, K. Sundaram, and D. Phillips Long-term immunization against the beta-subunit of ovine luteinizing hormone (oLH beta) has no adverse effects on pituitary function in rhesus monkeys. American Journal of Reproductive Immunology and Microbiology 15:92–98.Google Scholar
  64. Tietze, C., and S.L. Henshaw Induced Abortion: A World Review, 6th ed. New York: Alan Guttmacher Institute.Google Scholar
  65. Trussell, J., and K. Kost Contraceptive failure in the United States: a critical review of the literature. Studies in Family Planning 18:237–283.Google Scholar
  66. United Nations 1984 Recent Levels and Trends and Contraceptive Use as Assessed in 1983. New York: United Nations.Google Scholar
  67. Van Look, P.F.A. Post-ovulatory methods of fertility regulation. Pp. 153–173 in Research in Human Reproduction, WHO Special Programme of Research, Development and Research Training in Human Reproduction. Biennial Report, 1986–1987. Geneva: World Health Organization.Google Scholar
  68. Waites, G.M.H. Male fertility regulation. Pp. 199–223 in Research in Human Reproduction, WHO Special Programme of Research, Developrm nt and Research Training in Human Reproduction.Biennial Report, 1986- 1987. Geneva: World Health Organization. Google Scholar
  69. Wichmann, K., A. Vaheri, and T. Luukkainen 1982 Inhibiting herpes simplex virus type 2 infection in human epithelial cells by gossypol, a potent spermicidal and contraceptive agent. American Journal of Obstetrics and Gynecology 142(5):593–594.PubMedGoogle Scholar
  70. Wiedhaup, K. 1988 View of Contraceptive Development. Background paper for the Committee on Population, Subcommittee on Contraceptive Development, National Academy of Sciences.Google Scholar
  71. Zaneveld, L.J.D. 1988 SHUG device study. In Six Month Technical Report Summary, October 1, 1987-March 31, 1988. Norfolk: Contraceptive Research and Development Program, Eastern Virginia Medical School.Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Sheldon J. Segal

There are no affiliations available

Personalised recommendations